VeraKutsenko

The Profile

A career built on translation

Today Vera Kutsenko runs Atrix AI from an office on Broadway in Manhattan, and the company sells something deeply unglamorous and badly needed: a way for medical affairs teams at pharmaceutical and medical-device companies to take their messy real-world data and turn it into decisions they can actually stand behind. Atrix calls itself the trusted AI platform for life sciences. The word that matters in that sentence is "trusted." In a regulated industry, an answer you cannot defend is worse than no answer at all.

That is the work now. It looks nothing like what came before it, and yet it is exactly the same work.

Kutsenko is a Cornell-trained computer scientist. She earned her bachelor's in computer science there and stayed for a master's, then went and did the thing ambitious engineers did in the 2010s: she shipped at scale. At Facebook she worked on Internet.org, the effort to bring connectivity to people who had none. At Uber she became a senior engineer leading work on the mobile app, the part of the product that hundreds of millions of people actually touched. She co-authored a paper on distributed networking somewhere in there, too. This is a serious technical resume, the kind that usually leads to a comfortable staff-engineer title and a long, quiet tenure.

She left it to sell plants.

The plant years

In 2020, as a pandemic turned every apartment-dweller into an amateur horticulturalist, Kutsenko co-founded Neverland with Hayley Leibson. The two had met through a women-in-tech networking group in San Francisco and bonded over a shared love of plants. This was not a thesis cooked up on a whiteboard. Kutsenko kept her own plant nursery, which she tended by hand. She is also, for the record, a certified personal trainer. Range is a feature, not a bug.

Neverland was a marketplace, the hardest kind of company to build, connecting mom-and-pop garden shops with the surge of new plant parents. The clever part was the content. The team pulled from USDA agricultural APIs and translated the botanical jargon into plain language a nervous fern-owner could follow. Plant care, made legible. The company went through Y Combinator's W21 batch and raised $4.7 million from a notable roster: Obvious Ventures, Maveron, Kimbal Musk, and Y Combinator itself. Kutsenko cold-emailed venture capitalists into that round, a skill she has talked about openly since.

And then it didn't work. The unit economics of shipping living things bought online refused to add up, and Neverland wound down not long after it launched. Here is the part worth noting: Kutsenko said so, plainly, on the record. No quiet disappearance, no rebrand into stealth. A founder who names a failure out loud is handing you a reason to trust her next move, and people did.

From "Databricks 2.0" to medical affairs

Atrix did not arrive fully formed. In 2023 Kutsenko described it as "building Databricks 2.0 for marketing data," a no-code AI tool to help marketing teams make smarter calls on budget and resources. That is a perfectly reasonable startup. It is also not the one she ended up running. The company found its real customer in life sciences, where the data is genuinely hard, the stakes are genuinely high, and "trusted" is not a marketing word but a regulatory requirement.

The throughline from ferns to pharma is not a stretch. At Neverland she took "super science-y terms" and made them legible to plant buyers. At Atrix she takes the dense, regulated, real-world evidence that pharma and med-device companies generate and makes it legible to the medical affairs teams who have to act on it. Same instinct, different jargon, far higher stakes. Her pitch for the work is blunt: insights and automations are useless if you can't act on them.

That conviction has turned her into a regular on the conference circuit - Digital Pharma East, Fierce DPE, a string of medical affairs summits - where she argues against the industry's favorite habit of talking about what AI might someday do, and for the far less glamorous question of what it can do right now. She has put that view into writing too, authoring a widely shared guide on AI in medical affairs that reads less like a sales deck and more like a working operator's field notes.

Atrix is small - around thirteen people - and that is the point at this stage. A focused team, a hard problem, a customer who will not tolerate a wrong answer dressed up as a confident one. Kutsenko has done the big-company thing and the venture-darling thing and the public-failure thing. What she is doing now is the version that draws on all three: build something technically serious, sell it honestly, and refuse to ship an insight nobody can use.

Why she's worth watching

The easy story about Vera Kutsenko is the zigzag: Facebook, Uber, plants, pharma. The truer story is the straight line hiding inside it. Every chapter is the same move performed in a new domain - find the thing that is too complicated for the person who has to decide, and make it simple enough to decide on. She is not chasing whatever is hot. She keeps doing one specific job, and she keeps getting more serious about where she does it. A houseplant left to die is a sad afternoon. A pharma decision made on data nobody could read is something else entirely. She seems to know the difference, and to have built her current company around it.